title: Quantitative assessment of the association between TP53 Arg72Pro polymorphism and risk of glioma.
abstract: Many studies have investigated on the association between TP53 Arg72Pro polymorphism and risk of glioma, but the impact of TP53 Arg72Pro polymorphism on glioma risk is unclear owing to the obvious inconsistence among those studies. To shed light on these inconclusive findings and get a quantitative assessment of the association between the TP53 Arg72Pro polymorphism and risk of glioma, we conducted a meta-analysis of eligible studies. We searched PubMed and Embase databases for studies investigating on the association between the TP53 Arg72Pro polymorphism and risk of glioma. The pooled odds ratios (OR) with their 95% confidence intervals (95% CI) was calculated to assess the association between the TP53 Arg72Pro polymorphism and risk of glioma. A total of 12 studies were finally included into the meta-analysis. Meta-analysis of the 12 studies showed that TP53 Arg72Pro polymorphism was not associated with the risk of glioma (OR(Pro vs. Arg) = 1.07, 95% CI 0.93∼1.22; OR(ProPro vs. ArgArg) = 1.02, 95% CI 0.85∼1.22; OR(ProPro/ArgPro vs. ArgArg )= 1.06, 95% CI 0.85∼1.34; and OR(ProPro vs. ArgArg/ArgPro) = 1.07, 95% CI 0.91∼1.27). Subgroup analyses by ethnicity further identified that TP53 Arg72Pro polymorphism was not associated with the risk of glioma in Caucasians. However, there was a mild association between the TP53 Arg72Pro polymorphism and risk of glioma in Asians (OR(ProPro vs. ArgArg/ArgPro) = 1.42, 95% CI 1.00∼2.02). Thus, there is limited evidence for the association between the TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians.
authors.affiliation: Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, 250013, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Danni
authors.initials: D
authors.lastname: Li
authors.forename: Yanshuang
authors.initials: Y
authors.lastname: Li
authors.forename: Haixia
authors.initials: H
authors.lastname: Li
authors.forename: Jinbo
authors.initials: J
authors.lastname: Sun
authors.forename: Xianfeng
authors.initials: X
authors.lastname: Li
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Li
mesh_terms: D019943:Amino Acid Substitution; D001932:Brain Neoplasms / Q000208:ethnology / Q000235:genetics*; D003062:Codon; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005910:Glioma / Q000235:genetics*; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D012306:Risk; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D003062:Codon; D016159:Tumor Suppressor Protein p53
references.citation: Nat Genet. 2003 Mar;33(3):357-65
references.pmid: 12567188
references.citation: Genet Mol Res. 2008 Feb 26;7(1):207-16
references.pmid: 18393224
references.citation: Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
references.pmid: 17380161
references.citation: J Invest Dermatol. 2011 Mar;131(3):781-2
references.pmid: 21191409
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61
references.pmid: 17684142
references.citation: Science. 2005 Sep 9;309(5741):1732-5
references.pmid: 16151013
references.citation: Cancer Lett. 2013 May 1;331(2):139-46
references.pmid: 23340179
references.citation: J Neurooncol. 2007 May;82(3):229-37
references.pmid: 17151932
references.citation: Adv Exp Med Biol. 2012;746:2-11
references.pmid: 22639155
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Exp Mol Pathol. 2011 Apr;90(2):167-72
references.pmid: 21115003
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cell. 2012 Mar 30;149(1):36-47
references.pmid: 22464322
references.citation: Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):98-103
references.pmid: 15950766
references.citation: Int J Cancer. 2011 Aug 15;129(4):920-30
references.pmid: 20886596
references.citation: Nat Med. 2004 Aug;10(8):789-99
references.pmid: 15286780
references.citation: BMJ. 1998 Feb 7;316(7129):469; author reply 470-1
references.pmid: 9492685
references.citation: Cancer Biother Radiopharm. 2013 Apr;28(3):248-53
references.pmid: 23573956
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2220-3
references.pmid: 16172235
references.citation: Tumour Biol. 2013 Jun;34(3):1879-85
references.pmid: 23645212
references.citation: Cancer Genet Cytogenet. 2007 Sep;177(2):103-7
references.pmid: 17854663
references.citation: Nat Rev Cancer. 2009 Feb;9(2):95-107
references.pmid: 19165225
references.citation: Cancer Res. 2004 Aug 15;64(16):5560-3
references.pmid: 15313891
references.citation: Tumour Biol. 2013 Oct;34(5):3003-13
references.pmid: 23712607
references.citation: Cancer Genet Cytogenet. 2008 Jan 1;180(1):14-9
references.pmid: 18068527
references.citation: Cancer Genet. 2012 Dec;205(12):613-21
references.pmid: 23238284
references.citation: J Neurooncol. 2012 Oct;110(1):49-57
references.pmid: 22886512
references.citation: Neurology. 2009 Jan 27;72(4):332-6
references.pmid: 19171829